A retrospective single-center analysis of CD-19 directed CAR T-cell therapy in relapsed/refractory mantle cell lymphoma

Titas BanerjeeDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA

https://orcid.org/0000-0001-8077-7888 View further author information

Matthew NewmanDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information

Andy ChenDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information

Richard T. MaziarzDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information

Levanto SchachterDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information

Stephen E. SpurgeonDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information

Anusha VallurupalliDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USACorrespondence[email protected]

https://orcid.org/0000-0002-5003-807X View further author information

show all

Click to increase image sizeClick to decrease image size

Disclosure statement

SES: research funding: Genentech, Janssen, Pharmacyclics, Bristol Meyers/Celgene, Merck, Gilead Sciences, Acerta Pharma, BeiGene, Genmab, Incyte, and Morphosys. Consultancy: Genetech Advisory Board: Astra Zeneca and Janssen. RTM: research funding: BMS, Novartis, and Orca Bio. Consultant services: CRISPR Therapeutics, Incyte, Novartis, Bristol-Myers Squibb/Celgene, Allovir, and Gilead/Kite. Scientific Advisory Board: Artiva Therapeutics. DSMB membership: Novartis, Athersys, Vor Pharma, and Century Therapeutics. AC: clinical trial funding: Novartis, Fate Therapeutics, and AstraZeneca. Consultancy: Kite, Intellia Therapeutics, and Elsevier. AV: clinical trial funding: Genmab, Genentech, and ADC Therapeutics.

Additional information

Funding

This work was funded by the Knight Cancer Institute’s Leukemia and Lymphoma Distinguished Scholar Fund.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A retrospective single-center analysis of CD-19 directed CAR T-cell therapy in relapsed/refractory mantle cell lymphoma

Information for

Open access

Opportunities

Help and information

A retrospective single-center analysis of CD-19 directed CAR T-cell therapy in relapsed/refractory mantle cell lymphoma

Disclosure statement

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature